<DOC>
	<DOCNO>NCT00390156</DOCNO>
	<brief_summary>RATIONALE : Imatinib may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , bevacizumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , cyclophosphamide , work different way stop growth tumor cell , either kill cell stop dividing . Bevacizumab cyclophosphamide may also stop growth tumor cell block blood flow tumor . Imatinib bevacizumab may help cyclophosphamide work well make tumor cell sensitive drug . Giving cyclophosphamide day together imatinib bevacizumab may kill tumor cell . PURPOSE : This phase I trial study side effect best dose imatinib give together bevacizumab cyclophosphamide treat patient refractory metastatic solid tumor .</brief_summary>
	<brief_title>Imatinib , Bevacizumab , Cyclophosphamide Patients With Refractory Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose imatinib give together bevacizumab metronomic cyclophosphamide patient refractory metastatic solid tumor . - Determine safety profile regimen patient . Secondary - Determine effect cyclophosphamide bevacizumab imatinib pharmacokinetics . - Determine patient treat regimen achieve plasma level cyclophosphamide predict antiangiogenic . - Determine effect regimen number circulate endothelial cell , endothelial progenitor cell , activate endothelial cell , circulate tumor cell . - Determine effect regimen parameter measure CT scan perfusion ( e.g. , regional blood flow , blood volume , permeability-surface area product , mean transit time ) . OUTLINE : This nonrandomized , open-label , pilot , dose-escalation study imatinib . Patients receive oral cyclophosphamide oral imatinib daily day 1-28 bevacizumab IV day 1 15 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos imatinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis solid tumor Advanced metastatic disease* NOTE : *With exception colorectal lung cancer patient , patient must receive approval insurance carrier allow coverage/payment study drug bevacizumab Refractory standard therapy OR standard therapy exist No advanced ovarian cancer peritoneal carcinomatosis No metastases cancer cause significant ascites No lung malignancy follow characteristic : In close proximity major vessel Centrally locate Cavitary Squamous histology Hemoptysis &gt; ½ teaspoon per day PATIENT CHARACTERISTICS : ECOG performance status 01 Platelet count ≥ 100,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Bilirubin &lt; 2 mg/dL AST ALT &lt; 3 time upper limit normal Creatinine &lt; 2 mg/dL Urine protein : creatinine ratio ≤ 1.0 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able tolerate oral therapy No bleeding diatheses coagulopathy No impairment gastrointestinal ( GI ) function GI disease may affect alter absorption imatinib mesylate and/or cyclophosphamide ( e.g. , malabsorption syndrome , history total gastrectomy/significant small bowel resection ) No abdominal fistula , GI perforation , intraabdominal abscess within past 6 month No uncontrolled hypertension ( i.e. , blood pressure &gt; 150/100 mm Hg ) No uncontrolled cardiovascular disease , include follow : Coronary artery disease Uncontrolled cardiac arrhythmia Symptomatic congestive heart failure ( i.e. , New York Heart Association class IIIV ) Unstable angina pectoris Clinically significant peripheral vascular disease No arterial thromboses within past year , include follow : Transient ischemic attack Myocardial infarction Cerebrovascular event Unstable angina Angina require medical surgical intervention Clinically significant peripheral artery disease Any arterial thromboembolic event No interstitial pneumonia extensive symptomatic interstitial fibrosis lung No serious nonhealing wound , ulcer , bone fracture No active second malignancy except nonmelanoma skin cancer cervical carcinoma situ unless therapy complete &lt; 30 % risk relapse exist No active infection know HIV infection No history allergic reaction ( ≥ grade 3 4 ) compound similar chemical biologic composition cyclophosphamide ( i.e. , alkylating agent ) No history noncompliance medical regimens No known intolerance hypersensitivity reaction bevacizumab , imatinib mesylate , cyclophosphamide No significant medical illness , psychiatric illness , social situation , opinion investigator , would limit compliance study requirement No inability grant reliable informed consent PRIOR CONCURRENT THERAPY : No major surgical procedure within past 28 day anticipate major surgery study treatment except placement venous access device surgery diagnostic study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>refractory</keyword>
	<keyword>prior treatment</keyword>
	<keyword>solid tumor</keyword>
	<keyword>phase I</keyword>
	<keyword>phase 1</keyword>
</DOC>